Cancer.Net Specialty Editor: Lung Cancer
MD Anderson Cancer Center, Houston, TX
Dr. Anne Tsao is Professor of Medical Oncology at the University of Texas MD Anderson Cancer Center (MDACC) specializing in thoracic medical oncology. She is a leader in her field for the study of malignant mesothelioma and thoracic oncology.
Dr. Tsao earned her medical degree from the University of Chicago Pritzker School of Medicine. She completed her internship and residency at Indiana University in Indianapolis and her medical oncology fellowship at the University of Texas MDACC, where she joined the faculty after completing her training. Board certified in both internal medicine and medical oncology, Dr. Tsao currently serves as Director of the Mesothelioma Program and Director of the Thoracic Chemo-radiation Program at MDACC.
Her research focuses on individualizing cancer therapy through understanding the molecular mechanisms of disease. Dr. Tsao is the principal investigator of several active clinical trials at MDACC and has led numerous trials as the international and national principal investigator. She currently serves as Co-Chair of the MDACC Clinical Research Committee.
Dr. Tsao has been involved in more than 100 publications in several high-impact journals and has several first and last-author publications in Journal of Clinical Oncology, CA Cancer, Cancer Epidemiology, Biomarkers & Prevention (CEBP), Journal of Thoracic Oncology, Cancer Cell, Nature Medicine Clinical Oncology, and Molecular Cancer Therapeutics. She has also received numerous awards, including an ASCO Merit Award, MD Anderson Achievement in Research Award, ASCO Young Investigator Award, ASCO Career Development Award, NIH Clinician Scientist K12 Award, and Head and Neck SPORE Career Development Award. She has served as Program Project Leader on several large grants, including the Department of Defense PROSPECT grant.
Dr. Tsao is highly active in oncology societies both nationally and internationally. This includes serving on the Scientific Advisory Committee and chairing sessions for the American Radium Society, Chair of the Communications Committee for International Association for the Study of Lung Cancer (IASLC), and Mesothelioma Applied Research Foundation (MARF). She also serves on the SWOG Executive Lung Committee, SWOG Mesothelioma Steering Committee, DSMB for NRG Thoracic Oncology, and NRG Lung Executive Committee. For ASCO, she was selected to be in the ASCO Leadership Development Program, and she has subsequently been the track leader for the Cancer Education – Professional Development, track leader for the Cancer Education – Lung, served on the Professional Development Committee, ASCO Lifelong Learning Committee – MOC Lung Committee, and Government Relations Committee. She also assists ASCO/AACR in lobbying congressional leaders for improved research funding for cancer research.
Disclosure: In the past two years, Dr. Tsao has served as a consultant and/or advisor for Astellas Pharma, Boehringer Ingelheim, Genentech/Roche, Imedex, Lilly, MedImmune, Bristol-Meyers Squibb, Ariad, EMD Serono, Astra-Zeneca, Takeda, Epizyme, and Novartis and has received research funding from Genentech/Roche (Inst), MedImmune (Inst), Merck (Inst), Millennium, Eli Lilly, Polaris, Boehringer-Ingelheim, Bristol-Meyers Squibb, Ariad, Takeda, Epizyme, and Seattle Genetics.
Last updated: September 2018